Preliminary Study of hsa-mir-626 Change in the Cerebrospinal Fluid in Parkinson's Disease
Related Experiment Video
Updated: Nov 16, 2025
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
Li-Xia Qin1, Jie-Qiong Tan2, Hai-Nan Zhang1
1Department of Neurology, The Second Xiangya Hospital, Changsha, China.
Context:
A host of microRNAs have been reported to suppress tumor growth, invasion, and metastasis and play roles in neurodegeneration disorders. Moreover, microRNA changes are found in the peripheral blood, cerebrospinal fluid (CSF), and brain tissues of central nervous system diseases, including glioma, Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis, and depression. Compared with other body fluids, CSF can reflect the brain pathological processes more accurately.
Aims:
To understand whether microRNA expression may be misregulated in patients with PD, and further discover potential diagnostic biomarkers and promising therapeutic targets for PD.
Materials And Methods:
Here, through real-time reverse-transcription polymerase chain reaction (RT-PCR), we compared CSF microRNA from 15 PD patients, 11 AD patients, and 16 controls with other neurologic disorders, such as encephalitis and Guillain-Barre syndrome.
Results:
Finally, we identified hsa-miR-626 changes in the CSF of PD patients. The mean expression level of hsa-miR-626 was significantly reduced in the CSF of PD patients compared with AD patients and controls.
Conclusions:
Our approach provides a preliminary research for identifying biomarkers in the CSF that could be used for the detection, diagnosis, and monitoring of PD.
Insights
Researchers found reduced levels of microRNA hsa-miR-626 in cerebrospinal fluid (CSF) of Parkinson
Area of Science:
- Neuroscience
- Molecular Biology
- Biomarker Discovery
Background:
- MicroRNAs (miRNAs) are implicated in tumor suppression and neurodegenerative disorders.
- Altered miRNA profiles are observed in central nervous system diseases, detectable in cerebrospinal fluid (CSF).
- CSF offers a more accurate reflection of brain pathology than other bodily fluids.
Purpose of the Study:
- To investigate potential misregulation of miRNA expression in Parkinson's disease (PD).
- To identify diagnostic biomarkers and therapeutic targets for PD using miRNA analysis.
Main Methods:
- Real-time reverse-transcription polymerase chain reaction (RT-PCR) was employed.
- CSF miRNA levels were compared between 15 PD patients, 11 Alzheimer's disease (AD) patients, and 16 controls.
Main Results:
- A significant reduction in hsa-miR-626 expression was identified in the CSF of PD patients.
- This reduction was observed when compared to both AD patients and control groups.
Conclusions:
- The study presents preliminary findings for identifying CSF biomarkers for PD detection.
- This research supports the potential use of miRNAs in diagnosing and monitoring Parkinson's disease.
